Whether you are a new T1D Family, a TrialNet participant, a healthcare provider, or a researcher — you'll find resources here.
We’re here to help you after a new T1D diagnosis. Get answers to frequently asked questions and learn about clinical studies testing ways to maintain insulin production.
While you wait for screening results, get answers to your questions, find out about next steps, and learn more about TrialNet’s Pathway to Prevention.
Your T1D families are important to you. Learn how easy it is to connect your patients with world-class T1D research.
Dear TrialNet Family,
TrialNet has been investigating the role of oral insulin in T1D for nearly 20 years. Most recently, we completed the Oral Insulin Prevention Study—the largest study of its kind, conducted over 10 years with 560 relatives of people with T1D.
As we announce the study findings, I want to take this opportunity to recognize this incredible accomplishment and thank everyone involved.
First and foremost, on behalf of everyone in TrialNet and type 1 diabetes researchers around the world, I want to say a heartfelt thank you to the families who participated in the study. Please know you have and will continue to make a difference in our mission to find a way to delay, prevent and ultimately cure type 1 diabetes.
To the TrialNet nurses and healthcare providers who took such great care of participating families and upheld the highest research standards, we greatly appreciate your hard work and dedication.
To fellow researchers and scientists in and out of TrialNet, let this be a reminder that our time and efforts are impactful.
We would also like to thank the National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the American Diabetes Association and JDRF for their continued support. We also thank Congress for funding the Special Diabetes Program, an important program that provides critical funding for NIH T1D research.
I look forward to sharing more accomplishments as we work toward our ultimate goal: a future without T1D.
Sincerely,Carla Greenbaum, M.D.
Topline results of this 10-year TrialNet study were shared at the American Diabetes Association’s 77th Scientific Sessions on June 12, 2017. Now, we share them with you.
This study is an important step toward determining oral insulin’s role in delaying disease progression. TrialNet is considering conducting new trials using oral insulin to delay disease progression; but more work needs to be done.
Results of another important study, Exploring Immune Effects of Oral Insulin in Relatives at Risk for T1D, are expected later this year. This study is looking at how different doses and regimens of oral insulin effect immune response
In addition, two other prevention studies currently underway are testing the drugs Abatacept and Teplizumab to see if they can delay or prevent disease progression prior to diagnosis. TrialNet will also be launching new type 1 diabetes prevention trials and encourages all family members to get screened through the Pathway to Prevention study.
A big thank you to our amazing participants who made this research possible!
Oral Insulin study participant resources are available here.
If you are a current participant in the Immune Effects of Oral Insulin study and have questions about your study or the Oral Insulin study results, please contact your study team or email@example.com.
I am a current TrialNet Participant
I am a member of the Media
I am a Health Care Provider
I am a Researcher and would like to use samples